Clinical Trials Logo

Clinical Trial Summary

Food allergy is a potentially life-threatening condition, and its prevalence continues to increase despite public health efforts. There are currently no known therapies that can reliably prevent food-induced anaphylaxis. This is an open-label study designed to determine the ability acalabrutinib to prevent signs and symptoms of anaphylaxis during an oral food challenge in food-allergic adults.

Clinical Trial Description

Approximately 15 million people (including 8% of children) in the US have a food allergy and are at risk for life-threatening systemic reactions to foods. There is an unmet need for treatments capable of preventing such reactions. This is a phase II, single-center, open label trial involving the use of acalabrutinib (brand name Calquence®) to prevent food-induced anaphylaxis in adults with food allergy. Acalabrutinib is FDA-approved to treat certain medical conditions, but it is not approved to treat allergies. Adult participants with a physician-diagnosed food allergy to peanut and/or tree nuts will be enrolled. These participants will undergo an oral food challenge to peanut or a tree nut under close physician supervision to determine participants' baseline reactivity. After a rest period, the participants will take 4 oral doses of acalabrutinib 100 mg, and then repeat the oral food challenge to see if acalabrutinib will reduce participants' reactivity to peanut or tree nuts. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05038904
Study type Interventional
Source Johns Hopkins University
Contact Ragha Suresh, MD
Phone 410-803-3104
Email [email protected]
Status Recruiting
Phase Phase 2
Start date November 2021
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Completed NCT02552537 - iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions Phase 4
Completed NCT01634737 - Crustacean Allergy and Dust Mites Sensitization N/A
Active, not recruiting NCT04887441 - Allergology: Information, Data and Knowledge Organization
Recruiting NCT03265262 - The Basophil Activation Test as a Diagnostic Tool in Pediatric Food Allergy N/A
Active, not recruiting NCT04186949 - Early Origins of Allergy and Asthma
Completed NCT02490007 - Pertussis Immunisation and Food Allergy
Recruiting NCT03151252 - Improvement of Foodallergy Diagnostic in Gastrointestinal Tract N/A
Completed NCT02159833 - Intranasal Diagnostics in Food Allergy: a Feasibility Study N/A
Completed NCT02354729 - Encouraging Allergic Young Adults to Carry Epinephrine N/A
Completed NCT02377284 - Prevention and Management of Food Allergies N/A
Completed NCT02640560 - One-year Survey of Anaphylaxis in Outpatient Children Allergic to Peanuts, Walnuts/Hazelnuts, Shellfish N/A
Recruiting NCT04606615 - Skin Barrier Abnormalities and Oxidative Stress Response
Completed NCT02223182 - Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy Phase 1/Phase 2
Completed NCT02295397 - Integrated Approaches to Food Allergen and Allergy Risk Management N/A
Terminated NCT02341040 - Evaluation of Potential Allergenicity of New Wheat Varieties
Completed NCT03349047 - Anxiety About Casual Exposure to Food Allergens N/A
Not yet recruiting NCT04761835 - STEP-IT-UP - Peanut Allergy Study for Infants Phase 2
Recruiting NCT04037176 - Behandling af Boern Med Foedevareallergi Med Omalizumab (Xolair) Phase 4
Completed NCT03463135 - A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients Phase 1